Genetics, Peptide Pathways, and Personalized Response The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, and FTO variants that relate to GLP-1 and related signaling pathways
It names three conditions together: a confirmed inadequate response to GLP-1 monotherapy at a therapeutic level, an inability to tolerate SGLT2 inhibitors or basal insulin, and no access to newer agents such as tirzepatide
That might indicate mild corrosion
The Phase 2 data showed that 92% of participants in the 4 mg group achieved at least 5% weight loss, 75% achieved at least 10%, and 60% achieved at least 15% at 48 weeks
Because the main benefit of both options is digital treatment planning, which is done in similar ways with both companies, KLOwen and LightForce likely achieve similar results in similar treatment times